Lilly bets on Metis's AI platform for tissue-targeted lipid nanoparticles
- Eli Lilly and Hong Kong-listed METiS TechBio agreed a collaboration worth up to about $1.1 billion to develop tissue-specific delivery technologies.
- METiS contributes its AiLNP platform for ionizable lipid discovery, combining a large lipid library, screening and a lipid language model.
- Metis gets a low double-digit-million upfront, plus development, regulatory and commercial milestones and single-digit tiered royalties; no candidates or indications were named.
💡 Points
The headline figure is almost all contingent, so the real signal is the low-eight-figure upfront: Lilly is buying an option on delivery chemistry, not an asset. Extra-hepatic LNP targeting is the bottleneck for genetic medicines, and Lilly keeps stacking deals around it. For competitors in LNP design, the question is whether AI-generated lipid libraries can show reproducible tissue selectivity in vivo.
Lilly partners with Hong Kong's Metis in $1.1B deal to bolster AI nanoparticle discovery ↗